Association between epicardial adipose tissue and transfusion-dependent β-thalassemia.
Michele Malagù, Federico Marchini, Filomena Longo...
https://pubmed.ncbi.nlm.nih.gov/41065927/Actively Recruiting
Led by University Hospital of Ferrara · Updated on 2026-02-24
350
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research aims to compare clinical, laboratory, and imaging differences between patients with beta-thalassemia who have atrial fibrillation and those who do not. It is an observational study conducted at a single center, collecting data from patients with major or intermediate thalassemia evaluated at the Cardiology Unit of the University Hospital of Ferrara from 2012 to 2022, and continuing prospectively for the next 10 years. The study also explores the impact of certain medications called SGLT2-inhibitors on these patients. Participants include beta-thalassemia patients who have undergone cardiological evaluations including electrocardiograms and echocardiograms. They are divided into groups based on whether they have atrial fibrillation paroxysmal, persistent, or permanent or no history of arrhythmia. The study involves retrospective data collection and ongoing prospective assessment over a 10-year period. During the study, researchers will review clinical and laboratory results, heart imaging, and rhythm evaluations to understand differences in characteristics and outcomes such as thromboembolism and atrial fibrillation recurrence. They will also assess the baseline amount of epicardial adipose tissue and examine the effects of SGLT2-inhibitors on hemoglobin levels over six months. Participants involvement may include follow-up cardiological evaluations and data collection for up to 10 years.
CONDITIONS
Atrial Fibrillation in Beta-Thalassemia
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital of Ferrara
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants undergo cardiological evaluations including clinical, laboratory, electrocardiographic, and imaging assessments.
1 visit (in-person)
Duration - Up to 10 years
Participants are observed over time for the prevalence and recurrence of atrial fibrillation and other clinical outcomes.
Periodic visits as part of routine cardiological follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Michele Malagù, Federico Marchini, Filomena Longo...
https://pubmed.ncbi.nlm.nih.gov/41065927/Federico Marchini, Maria Mele, Elena Marchetti...
https://pubmed.ncbi.nlm.nih.gov/41674122/University Hospital of Ferrara
Lead Sponsor